donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > LNTH Lantheus > Detailed Quotes

LNTH Lantheus

79.190
+0.620+0.79%
Close 08/08 16:00 ET
79.110
-0.08-0.10%
Post Mkt Price 08/08 16:40 ET
High
83.930
Open
79.010
Turnover
111.16M
Low
78.620
Pre Close
78.570
Volume
1.38M
Market Cap
5.44B
P/E(TTM)
188.55
52wk High
83.930
Shares
68.74M
P/E(Static)
Loss
52wk Low
22.200
Float Cap
5.22B
Bid/Ask %
-60.00%
Historical High
83.930
Shs Float
65.91M
Volume Ratio
0.81
Historical Low
1.760
Dividend TTM
--
Div Yield TTM
3300
P/B
9.60
Dividend LFY
--
Div Yield LFY
4167.19%
Turnover Ratio
2.09%
Amplitude
6.76%
Avg Price
80.706
Lot Size
1
Float Cap
5.22B
Bid/Ask %
-60.00%
Historical High
83.930
Shs Float
65.91M
Volume Ratio
0.81
Historical Low
1.760
Dividend TTM
--
P/B
9.60
Dividend LFY
--
Turnover Ratio
2.09%
Amplitude
6.76%
Avg Price
80.706
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
CEO: Heino, Mary Anne
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...